BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

UP Oncolytics Wins $75,000 Illinois Innovation Voucher To Advance Breakthrough Glioblastoma Therapy

UP Oncolytics, a biotech company in Rosalind Franklin University's Helix 51 biomedical incubator, was awarded an Illinois Innovation Voucher gran...

January 09, 2026 | News

Thermo Fisher Scientific Enrols First Patient In New CorEvitas Obesity Registry

Thermo Fisher Scientific Inc., the world leader in serving science,announced the enrollment of the first patient in the new PPD™ CorEvitas™ Obe...

January 08, 2026 | News

ProBioGen Signs Master Service Agreement With Zag Bio To Advance Thymus Targeted Antibody Programme

ProBioGen announced the signing of a Master Service Agreement ("MSA") with Zag Bio, Inc., a biotechnology company developing thymus-targete...

January 07, 2026 | News

C&R Research Deepens Indonesia Engagement Through Global Clinical Trial Capabilities

Accelerating Indonesia Collaboration through Global Clinical Capabilities C&R Research, founded in 1997 as Korea's first full-service Contract R...

January 06, 2026 | News

GenEditBio Secures US FDA IND Clearance For First In Vivo Genome Editing Trial In TGFBI Corneal Dystrophy

GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. F...

January 06, 2026 | News

Leading the Future of Care: Patient Organizations Driving Health System Transformation

Real Change Starts with Listening Across the Asia Pacific, Middle East, and Africa, healthcare systems are facing mounting pressures with rising rates of ...

January 05, 2026 | Opinion | By Sung Lee, Executive Director, Region Communications and Patient Advocacy, Asia Pacific, Middle East, Africa (APMA), Novartis

Senhwa Biosciences Advances CX 5461 Into ADC Combination Trial With Enhertu Backed By US NCI

Senhwa Biosciences has announced a significant clinical milestone with its investigational drug Pidnarulex CX 5461 advancing into a Phase 1...

December 30, 2025 | News

Alphamab Oncology Secures IND Acceptance In China For JSKN033 Phase II Cervical Cancer Study

Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcu...

December 30, 2025 | News

Sobi Secures Positive CHMP Opinion For Aspaveli In Rare Kidney Diseases

Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN If approved, Aspaveli (pegcetacoplan) would be the first C3G and primary IC-...

December 30, 2025 | News

Mondego Bio Selects ZE00 0388 As Lead Clinical Candidate And Prepares For Phase One Entry In 2026

Mondego Bio, a clinical-stage biotechnology company developing next-generation small-molecule immuno-oncology therapies, today announced the formal selecti...

December 25, 2025 | News

Promontory Therapeutics Exceeds Interim Efficacy Bar In Thymoma Study With PT 112

Three of the first 10 patients with thymoma evaluated by RECIST have partial responses. Findings exceed protocol requirement of two re...

December 24, 2025 | News

Ginkgo Bioworks Joins Carnegie Mellon Led ARPA H Programme To Advance At Home Cancer Detection

Ginkgo Bioworks announced its partnership with Carnegie-Mellon University (CMU) for an award by the Advanced Research Projects Agency for Health...

December 24, 2025 | News

Japan Approves Guardant360 CDx As First Blood Based Companion Diagnostic For ESR1 Mutations In Breast Cancer

Guardant360® CDx is the first companion diagnostic to be approved in Japan to identify ESR1 mutations in patients with hormone receptor-posit...

December 23, 2025 | News

Peijia Medical Secures China Regulatory Approval For TaurusTrio Transcatheter Aortic Valve System

Peijia Medical (9996.HK), a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, a...

December 16, 2025 | News

Stay Connected